The Novel Albumin-chitosan Core-shell Nanoparticles for Gene Delivery: Preparation, Optimization and Cell Uptake Investigation

Overview

Journal J Nanopart Res

Specialty Biomedical Engineering

Date 2013 Dec 24

PMID 24363607

Citations 20

Authors

Mahdi Karimi

Pinar Avci

Rezvan Mobasseri

Michael R Hamblin

Hossein Naderi-Manesh

Affiliations

Soon will be listed here.

Abstract

Natural polymers and proteins such as chitosan (CS) and albumin (Alb) have recently attracted much attention both in drug delivery and gene delivery. The underlying rationale is their unique properties such as biodegradability, biocompatibility and controlled release. This study aimed to prepare novel albumin-chitosan-DNA (Alb-CS-DNA) core-shell nanoparticles as a plasmid delivery system and find the best conditions for their preparation. Phase separation method and ionic interaction were used for preparation of Alb nanoparticles and Alb-CS-DNA core-shell nanoparticles, respectively. The effects of three important independent variables (1) CS/Alb mass ratio, (2) the ratios of moles of the amine groups of cationic polymers to those of the phosphate groups of DNA (N/P ratio), and (3) Alb concentration, on the nanoparticle size and loading efficiency of the plasmid were investigated and optimized through Box-Behnken design of response surface methodology (RSM). The optimum conditions were found to be CS/Alb mass ratio = 3, N/P ratio = 8.24 and Alb concentration = 0.1 mg/mL. The most critical factors for the size of nanoparticles and loading efficiency were Alb concentration and N/P ratio. The optimized nanoparticles had an average size of 176 ± 3.4 nm and loading efficiency of 80 ± 3.9 %. Cytotoxicity experiments demonstrated that the prepared nanoparticles were not toxic. The high cellular uptake of nanoparticles (~85 %) was shown by flow cytometry and fluorescent microscopy.

Citing Articles

Albumin Nanoparticle-Based Drug Delivery Systems.

Qu N, Song K, Ji Y, Liu M, Chen L, Lee R Int J Nanomedicine. 2024; 19:6945-6980.

PMID: 39005962 PMC: 11246635. DOI: 10.2147/IJN.S467876.

Chitosan-PEI passivated carbon dots for plasmid DNA and miRNA-153 delivery in cancer cells.

Thakur S, Saini R, Thakur N, Sharma R, Das J, Slama P Heliyon. 2023; 9(11):e21824.

PMID: 38034707 PMC: 10682126. DOI: 10.1016/j.heliyon.2023.e21824.

Innovative biosynthesis, artificial intelligence-based optimization, and characterization of chitosan nanoparticles by Streptomyces microflavus and their inhibitory potential against Pectobacterium carotovorum.

El-Naggar N, Bashir S, Rabei N, Saber W Sci Rep. 2022; 12(1):21851.

PMID: 36528632 PMC: 9759534. DOI: 10.1038/s41598-022-25726-w.

Nanotechnology in drug and gene delivery.

Hamimed S, Jabberi M, Chatti A Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(7):769-787.

PMID: 35505234 PMC: 9064725. DOI: 10.1007/s00210-022-02245-z.

Chitosan-coated bovine serum albumin nanoparticles for topical tetrandrine delivery in glaucoma: and assessment.

Radwan S, El-Moslemany R, Mehanna R, Thabet E, Abdelfattah E, El-Kamel A Drug Deliv. 2022; 29(1):1150-1163.

PMID: 35384774 PMC: 9004496. DOI: 10.1080/10717544.2022.2058648.

References

Bansal K, Kakde D, Gupta U, Jain N . Development and characterization of triazine based dendrimers for delivery of antitumor agent. J Nanosci Nanotechnol. 2010; 10(12):8395-404. DOI: 10.1166/jnn.2010.3003. View

Nagpal K, Singh S, Mishra D . Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo). 2010; 58(11):1423-30. DOI: 10.1248/cpb.58.1423. View

Kim T, Yu G, Choi H, Shim Y, Lee M, Choi J . Preparation of dexamethasone-based cationic liposome and its application to gene delivery in vitro. J Nanosci Nanotechnol. 2011; 11(2):1799-802. DOI: 10.1166/jnn.2011.3407. View

Kratz F . Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008; 132(3):171-83. DOI: 10.1016/j.jconrel.2008.05.010. View

Weber C, Coester C, Kreuter J, Langer K . Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 1999; 194(1):91-102. DOI: 10.1016/s0378-5173(99)00370-1. View

Arya G, Vandana M, Acharya S, Sahoo S . Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine. 2011; 7(6):859-70. DOI: 10.1016/j.nano.2011.03.009. View

Azarmi S, Tao X, Chen H, Wang Z, Finlay W, Lobenberg R . Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006; 319(1-2):155-61. DOI: 10.1016/j.ijpharm.2006.03.052. View

El-Aneed A . An overview of current delivery systems in cancer gene therapy. J Control Release. 2003; 94(1):1-14. DOI: 10.1016/j.jconrel.2003.09.013. View

Huang P, Kong Y, Li Z, Gao F, Cui D . Copper selenide nanosnakes: bovine serum albumin-assisted room temperature controllable synthesis and characterization. Nanoscale Res Lett. 2010; 5(6):949-56. PMC: 2894339. DOI: 10.1007/s11671-010-9587-0. View

10.

Nasti A, Zaki N, de Leonardis P, Ungphaiboon S, Sansongsak P, Rimoli M . Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res. 2009; 26(8):1918-30. DOI: 10.1007/s11095-009-9908-0. View

11.

de Souza Costa-Junior E, Pereira M, Mansur H . Properties and biocompatibility of chitosan films modified by blending with PVA and chemically crosslinked. J Mater Sci Mater Med. 2008; 20(2):553-61. DOI: 10.1007/s10856-008-3627-7. View

12.

Lavertu M, Methot S, Tran-Khanh N, Buschmann M . High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials. 2006; 27(27):4815-24. DOI: 10.1016/j.biomaterials.2006.04.029. View

13.

Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D . Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003; 257(1-2):169-80. DOI: 10.1016/s0378-5173(03)00134-0. View

14.

Kommareddy S, Amiji M . Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug Chem. 2005; 16(6):1423-32. DOI: 10.1021/bc050146t. View

15.

Lee D, Lockey R, Mohapatra S . Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans. J Nanosci Nanotechnol. 2006; 6(9-10):2860-6. DOI: 10.1166/jnn.2006.465. View

16.

Zhang S, Kucharski C, Doschak M, Sebald W, Uludag H . Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery. Biomaterials. 2009; 31(5):952-63. DOI: 10.1016/j.biomaterials.2009.10.011. View

17.

Weber C, Kreuter J, Langer K . Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm. 2000; 196(2):197-200. DOI: 10.1016/s0378-5173(99)00420-2. View

18.

Rahbari R, Sheahan T, Modes V, Collier P, Macfarlane C, Badge R . A novel L1 retrotransposon marker for HeLa cell line identification. Biotechniques. 2009; 46(4):277-84. PMC: 2696096. DOI: 10.2144/000113089. View

19.

Che H, Muthiah M, Ahn Y, Son S, Kim W, Seonwoo H . Biodegradable particulate delivery of vascular endothelial growth factor plasmid from polycaprolactone/polyethylenimine electrospun nanofibers for the treatment of myocardial infarction. J Nanosci Nanotechnol. 2011; 11(8):7073-7. DOI: 10.1166/jnn.2011.4862. View

20.

Duan Y, Zheng J, Han S, Wu Y, Wang Y, Li D . A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy. J Control Release. 2008; 127(2):173-9. DOI: 10.1016/j.jconrel.2008.01.016. View